A carregar...
Ocular Changes in Metastatic Melanoma Patients Treated with MEK Inhibitor Cobimetinib and BRAF Inhibitor Vemurafenib
BACKGROUND: Mitogen-activated protein kinase kinase (MEK) inhibitor cobimetinib and V-raf murine sarcoma viral oncogene homolog B1 (BRAF) inhibitor vemurafenib have significantly improved the prognosis of BRAF-mutated metastatic melanoma. Some ocular symptoms and signs were recently recognized to fo...
Na minha lista:
| Publicado no: | Radiol Oncol |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Sciendo
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6043881/ https://ncbi.nlm.nih.gov/pubmed/30018526 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2478/raon-2018-0002 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|